ASTRAZENECA PLC (ZEG.DE) Fundamental Analysis & Valuation

FRA:ZEG • GB0009895292

Current stock price

160.7 EUR
+0.95 (+0.59%)
Last:

This ZEG.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. ZEG.DE Profitability Analysis

1.1 Basic Checks

  • In the past year ZEG was profitable.
  • In the past year ZEG had a positive cash flow from operations.
  • Each year in the past 5 years ZEG has been profitable.
  • Each year in the past 5 years ZEG had a positive operating cash flow.
ZEG.DE Yearly Net Income VS EBIT VS OCF VS FCFZEG.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

1.2 Ratios

  • ZEG has a better Return On Assets (8.96%) than 63.64% of its industry peers.
  • ZEG's Return On Equity of 21.01% is fine compared to the rest of the industry. ZEG outperforms 65.45% of its industry peers.
  • ZEG has a better Return On Invested Capital (13.63%) than 65.45% of its industry peers.
  • ZEG had an Average Return On Invested Capital over the past 3 years of 12.48%. This is significantly below the industry average of 17.75%.
  • The 3 year average ROIC (12.48%) for ZEG is below the current ROIC(13.63%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 8.96%
ROE 21.01%
ROIC 13.63%
ROA(3y)7.2%
ROA(5y)5.03%
ROE(3y)17.82%
ROE(5y)12.53%
ROIC(3y)12.48%
ROIC(5y)10.5%
ZEG.DE Yearly ROA, ROE, ROICZEG.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20

1.3 Margins

  • ZEG has a better Profit Margin (17.41%) than 69.09% of its industry peers.
  • In the last couple of years the Profit Margin of ZEG has grown nicely.
  • ZEG has a Operating Margin (23.86%) which is comparable to the rest of the industry.
  • In the last couple of years the Operating Margin of ZEG has grown nicely.
  • With an excellent Gross Margin value of 81.31%, ZEG belongs to the best of the industry, outperforming 85.45% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ZEG has remained more or less at the same level.
Industry RankSector Rank
OM 23.86%
PM (TTM) 17.41%
GM 81.31%
OM growth 3Y6.24%
OM growth 5Y7.63%
PM growth 3Y32.91%
PM growth 5Y7.71%
GM growth 3Y0.34%
GM growth 5Y0.28%
ZEG.DE Yearly Profit, Operating, Gross MarginsZEG.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. ZEG.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ZEG is creating some value.
  • The number of shares outstanding for ZEG remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for ZEG has been increased compared to 5 years ago.
  • ZEG has a better debt/assets ratio than last year.
ZEG.DE Yearly Shares OutstandingZEG.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B
ZEG.DE Yearly Total Debt VS Total AssetsZEG.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B

2.2 Solvency

  • ZEG has an Altman-Z score of 3.77. This indicates that ZEG is financially healthy and has little risk of bankruptcy at the moment.
  • ZEG has a Altman-Z score of 3.77. This is comparable to the rest of the industry: ZEG outperforms 54.55% of its industry peers.
  • The Debt to FCF ratio of ZEG is 3.42, which is a good value as it means it would take ZEG, 3.42 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 3.42, ZEG is in the better half of the industry, outperforming 63.64% of the companies in the same industry.
  • A Debt/Equity ratio of 0.55 indicates that ZEG is somewhat dependend on debt financing.
  • With a decent Debt to Equity ratio value of 0.55, ZEG is doing good in the industry, outperforming 61.82% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 3.42
Altman-Z 3.77
ROIC/WACC1.49
WACC9.14%
ZEG.DE Yearly LT Debt VS Equity VS FCFZEG.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.3 Liquidity

  • ZEG has a Current Ratio of 0.94. This is a bad value and indicates that ZEG is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of ZEG (0.94) is worse than 81.82% of its industry peers.
  • A Quick Ratio of 0.72 indicates that ZEG may have some problems paying its short term obligations.
  • ZEG has a worse Quick ratio (0.72) than 74.55% of its industry peers.
Industry RankSector Rank
Current Ratio 0.94
Quick Ratio 0.72
ZEG.DE Yearly Current Assets VS Current LiabilitesZEG.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. ZEG.DE Growth Analysis

3.1 Past

  • ZEG shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.34%.
  • The Earnings Per Share has been growing by 15.04% on average over the past years. This is quite good.
  • Looking at the last year, ZEG shows a quite strong growth in Revenue. The Revenue has grown by 8.63% in the last year.
  • ZEG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.15% yearly.
EPS 1Y (TTM)-1.34%
EPS 3Y6.74%
EPS 5Y15.04%
EPS Q2Q%-49.28%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y9.82%
Revenue growth 5Y17.15%
Sales Q2Q%4.11%

3.2 Future

  • The Earnings Per Share is expected to grow by 15.20% on average over the next years. This is quite good.
  • ZEG is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.82% yearly.
EPS Next Y30.41%
EPS Next 2Y20.69%
EPS Next 3Y17.63%
EPS Next 5Y15.2%
Revenue Next Year6.06%
Revenue Next 2Y5.93%
Revenue Next 3Y6.22%
Revenue Next 5Y6.82%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ZEG.DE Yearly Revenue VS EstimatesZEG.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B
ZEG.DE Yearly EPS VS EstimatesZEG.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

4

4. ZEG.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 23.53, the valuation of ZEG can be described as rather expensive.
  • ZEG's Price/Earnings is on the same level as the industry average.
  • The average S&P500 Price/Earnings ratio is at 25.35. ZEG is around the same levels.
  • The Price/Forward Earnings ratio is 18.05, which indicates a rather expensive current valuation of ZEG.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of ZEG is on the same level as its industry peers.
  • When comparing the Price/Forward Earnings ratio of ZEG to the average of the S&P500 Index (22.61), we can say ZEG is valued slightly cheaper.
Industry RankSector Rank
PE 23.53
Fwd PE 18.05
ZEG.DE Price Earnings VS Forward Price EarningsZEG.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • ZEG's Enterprise Value to EBITDA is on the same level as the industry average.
  • ZEG's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 34.09
EV/EBITDA 16.14
ZEG.DE Per share dataZEG.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of ZEG may justify a higher PE ratio.
  • A more expensive valuation may be justified as ZEG's earnings are expected to grow with 17.63% in the coming years.
PEG (NY)0.77
PEG (5Y)1.56
EPS Next 2Y20.69%
EPS Next 3Y17.63%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. ZEG.DE Dividend Analysis

5.1 Amount

  • ZEG has a Yearly Dividend Yield of 1.64%.
  • Compared to an average industry Dividend Yield of 1.95, ZEG has a dividend in line with its industry peers.
  • ZEG's Dividend Yield is comparable with the S&P500 average which is at 1.89.
Industry RankSector Rank
Dividend Yield 1.64%

5.2 History

  • The dividend of ZEG has a limited annual growth rate of 3.33%.
Dividend Growth(5Y)3.33%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • 48.62% of the earnings are spent on dividend by ZEG. This is a bit on the high side, but may be sustainable.
  • ZEG's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP48.62%
EPS Next 2Y20.69%
EPS Next 3Y17.63%
ZEG.DE Yearly Income VS Free CF VS DividendZEG.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B
ZEG.DE Dividend Payout.ZEG.DE Dividend Payout, showing the Payout Ratio.ZEG.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

ZEG.DE Fundamentals: All Metrics, Ratios and Statistics

ASTRAZENECA PLC

FRA:ZEG (2/5/2026, 7:00:00 PM)

160.7

+0.95 (+0.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-10
Earnings (Next)04-29
Inst Owners49.17%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap249.13B
Revenue(TTM)58.74B
Net Income(TTM)10.22B
Analysts82.94
Price Target175.52 (9.22%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.64%
Yearly Dividend2.7
Dividend Growth(5Y)3.33%
DP48.62%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-25.37%
Min EPS beat(2)-60.38%
Max EPS beat(2)9.64%
EPS beat(4)2
Avg EPS beat(4)-12.23%
Min EPS beat(4)-60.38%
Max EPS beat(4)9.64%
EPS beat(8)4
Avg EPS beat(8)-5.74%
EPS beat(12)7
Avg EPS beat(12)-2.63%
EPS beat(16)11
Avg EPS beat(16)-0.36%
Revenue beat(2)1
Avg Revenue beat(2)-1.31%
Min Revenue beat(2)-4.83%
Max Revenue beat(2)2.2%
Revenue beat(4)1
Avg Revenue beat(4)-2.92%
Min Revenue beat(4)-5.08%
Max Revenue beat(4)2.2%
Revenue beat(8)4
Avg Revenue beat(8)-0.54%
Revenue beat(12)5
Avg Revenue beat(12)-0.86%
Revenue beat(16)6
Avg Revenue beat(16)-0.78%
PT rev (1m)5.49%
PT rev (3m)12.4%
EPS NQ rev (1m)-1.75%
EPS NQ rev (3m)-1.48%
EPS NY rev (1m)1.58%
EPS NY rev (3m)-0.37%
Revenue NQ rev (1m)-0.41%
Revenue NQ rev (3m)-0.71%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.59%
Valuation
Industry RankSector Rank
PE 23.53
Fwd PE 18.05
P/S 5.03
P/FCF 34.09
P/OCF 20.28
P/B 6.07
P/tB N/A
EV/EBITDA 16.14
EPS(TTM)6.83
EY4.25%
EPS(NY)8.9
Fwd EY5.54%
FCF(TTM)4.71
FCFY2.93%
OCF(TTM)7.93
OCFY4.93%
SpS31.94
BVpS26.46
TBVpS-5.67
PEG (NY)0.77
PEG (5Y)1.56
Graham Number63.77
Profitability
Industry RankSector Rank
ROA 8.96%
ROE 21.01%
ROCE 16.8%
ROIC 13.63%
ROICexc 14.63%
ROICexgc 59.47%
OM 23.86%
PM (TTM) 17.41%
GM 81.31%
FCFM 14.76%
ROA(3y)7.2%
ROA(5y)5.03%
ROE(3y)17.82%
ROE(5y)12.53%
ROIC(3y)12.48%
ROIC(5y)10.5%
ROICexc(3y)13.49%
ROICexc(5y)11.39%
ROICexgc(3y)81.92%
ROICexgc(5y)83.55%
ROCE(3y)15.36%
ROCE(5y)12.92%
ROICexgc growth 3Y-25.55%
ROICexgc growth 5Y0.81%
ROICexc growth 3Y9.13%
ROICexc growth 5Y9.72%
OM growth 3Y6.24%
OM growth 5Y7.63%
PM growth 3Y32.91%
PM growth 5Y7.71%
GM growth 3Y0.34%
GM growth 5Y0.28%
F-Score7
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 3.42
Debt/EBITDA 1.36
Cap/Depr 103%
Cap/Sales 10.05%
Interest Coverage 10.65
Cash Conversion 73.79%
Profit Quality 84.79%
Current Ratio 0.94
Quick Ratio 0.72
Altman-Z 3.77
F-Score7
WACC9.14%
ROIC/WACC1.49
Cap/Depr(3y)80.57%
Cap/Depr(5y)64.46%
Cap/Sales(3y)8.93%
Cap/Sales(5y)7.69%
Profit Quality(3y)99.49%
Profit Quality(5y)775.68%
High Growth Momentum
Growth
EPS 1Y (TTM)-1.34%
EPS 3Y6.74%
EPS 5Y15.04%
EPS Q2Q%-49.28%
EPS Next Y30.41%
EPS Next 2Y20.69%
EPS Next 3Y17.63%
EPS Next 5Y15.2%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y9.82%
Revenue growth 5Y17.15%
Sales Q2Q%4.11%
Revenue Next Year6.06%
Revenue Next 2Y5.93%
Revenue Next 3Y6.22%
Revenue Next 5Y6.82%
EBIT growth 1Y10.05%
EBIT growth 3Y16.67%
EBIT growth 5Y26.09%
EBIT Next Year23.4%
EBIT Next 3Y12.45%
EBIT Next 5Y11.39%
FCF growth 1Y19.18%
FCF growth 3Y6.21%
FCF growth 5Y31.64%
OCF growth 1Y22.88%
OCF growth 3Y14.12%
OCF growth 5Y24.88%

ASTRAZENECA PLC / ZEG.DE Fundamental Analysis FAQ

What is the fundamental rating for ZEG stock?

ChartMill assigns a fundamental rating of 5 / 10 to ZEG.DE.


What is the valuation status of ASTRAZENECA PLC (ZEG.DE) stock?

ChartMill assigns a valuation rating of 3 / 10 to ASTRAZENECA PLC (ZEG.DE). This can be considered as Overvalued.


How profitable is ASTRAZENECA PLC (ZEG.DE) stock?

ASTRAZENECA PLC (ZEG.DE) has a profitability rating of 7 / 10.


What is the valuation of ASTRAZENECA PLC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ASTRAZENECA PLC (ZEG.DE) is 23.53 and the Price/Book (PB) ratio is 6.07.


What is the earnings growth outlook for ASTRAZENECA PLC?

The Earnings per Share (EPS) of ASTRAZENECA PLC (ZEG.DE) is expected to grow by 30.41% in the next year.